
Opinion|Videos|February 27, 2026
How Nurse Practitioners Aid in Treatment Selection and Communication in EGFR+ NSCLC
Narjust Florez, MD, and Stephanie J. McDonald, MSN, FNP-BC, AOCNP, discuss how nurse practitioners add valuable insight to treatment selection in EGFR-mutated NSCLC.
Advertisement
Narjust Florez, MD, and Stephanie J. McDonald, MSN, FNP-BC, AOCNP, discuss the integral role nurse practitioners play in treatment planning for patients with EGFR-mutated non–small cell lung cancer. Florez explains how advanced practice providers contribute clinical insight into patient comorbidities, preferences, and functional status when selecting therapy. McDonald describes how ongoing patient interaction enables early identification of concerns that may influence treatment decisions and adherence.
Advertisement
Related to this article

The decision removes the triple-class–refractory requirement and allows melflufen use after at least 2 prior lines of therapy.

The FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.

Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL.

SER-155 showed early promise in reducing bloodstream infections in patients undergoing donor stem cell transplants for blood cancers.

Advances in endocrine therapy, immunotherapy, and ADCs frame unresolved breast cancer treatment questions ahead of BTG 2026.

During a recent OncLive Peer Exchange, multiple myeloma experts discussed how BCMA-directed therapies can be selected and sequenced.
Advertisement
Advertisement
Trending on OncLive
1
Cesalatamig Monotherapy Shows Dose-Dependent Activity in PD-(L)1 Inhibitor–Experienced NSCLC
2
Dr Banks on the Feasibility of Lifileucel in Select Metastatic Sarcomas
3
BCMA-Directed Bispecifics and ADCs Broaden Treatment Sequencing Options in R/R Myeloma
4
UV1 Vaccine Data Keep hTERT in Focus as an Immunotherapy Target in Recurrent Ovarian Cancer
5


